Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
October 31, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is...
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
October 17, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg and 2,000 mg doses in the single ascending dose (SAD) portion of the study and 300 mg,...
Sorrento Announces Publication of Data in Cell Press Journal Med Describing Discovery and Preclinical Efficacy of a Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) or IN (STI-9199)
October 14, 2022 14:56 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication in the Cell Press journal Med of data detailing work relating to the...
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
October 06, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key...
Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes
September 29, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library
September 15, 2022 15:34 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical...
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections
September 15, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved...
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
September 08, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and...
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
August 30, 2022 23:21 ET
|
Sorrento Therapeutics, Inc.
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan...